Gilead doubles down on HIV prevention, treatment amid Covid setbacks and awaiting FDA decision on long-acting candidate
Amid predictions of HIV advances unraveling during Covid, Gilead Sciences is doubling down on prevention, treatment options and on-the-ground community efforts, even as it awaits an FDA decision on its long-acting candidate.
At the AIDS 2022 conference beginning next week, Gilead will present new data and studies on HIV treatment Biktarvy and its long-acting PrEP and HIV candidate lenacapavir, but will also host a panel laying out the details — and importance — of community collaborations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.